In cooperation with cell press

Given the recent introduction of new biologics that target type 2 cytokines to treat severe allergic disease, we are accumulating a lot of new insights on type 2 immune responses in humans as well.

This meeting will not only focus on new effector and regulatory mechanisms of the type 2 immune response. It will also offer a number of talks taking a broader look on type 2 immunity, dealing with such topics as type 2 immunity in homeostasis, growth and repair, metabolism, neuro-immune interactions and cancer.

Understanding these alternative roles for type 2 immunity will be important to address the benefits and potential pitfalls of long-term inhibition of type 2 immunity by biologicals and could elucidate new therapeutic pathways for very common diseases like asthma, obesity, diabetes and cancer.

Abstracts can be submitted for the following topics:

• Tissue homeostasis and repair
• Type 2 Neuro-immune axis
• Type 2 in allergy, asthma & helminth infection
• Type 2 Immunity & Cancer
  
  

Poster information:
Format: A0 (841 x 1189 mm / 33.1 x 46.8 in), portrait orientation

Deadlines:

• Early Bird: 10 January 2019
• Late Registration: 7 February 2019
• Abstract deadline: 19 December 2018
  
  

Website link: https://vibconferences.be/event/type-2-immunity-in-homeostasis-and-disease  

Speakers including:

• Judi Allen, The University of Manchester, UK
• David Artis, Weill Cornell Medicine, US
• Ronald N. Germain, National Institutes of Health, US
• Elise Dalmas, INSERM, FR
• Stephen Joseph Galli, Stanford University, US
• Ana Domingos, The Instituto Gulbenkian de Ciência, PT
• Jean-Philippe Girard, CNRS - University of Toulouse, FR
• Philippe Jay, INSERM, FR
• Moro Kazuyo, Laboratory for Innate Immune systems, RIKEN IMS, JP
• Andrew McKenzie, MRC Laboratory of Molecular Biology, UK
• Anna Molofsky, University of California-San Francisco, US
• Ariel Munitz, Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, IL
• Marion Pepper, Department of Immunology, University of Washington, US
• Wayne Shreffler, Massachusetts General Hospital, US
• Henrique Veiga-Fernandes, Champalimaud Centre for the Unknown, PT
• Steve F. Ziegler, Benaroya Research Institute, US
• Bart Lambrecht, VIB-UGent Center for Inflammation Research, BE
• Richard Locksley, Department of Medicine (Infectious Diseases), University of California San Francisco, US